‘Exasperation’ over European deadlock on grace period European businesses can’t agree on how to move forward with talks on harmonising international patent laws By Rory O’Neill January 19 2022
Europe: key patent issues counsel should monitor this year Between AI inventorship, SEPs, and the UPC, there’s plenty to keep European attorneys busy in 2022 By Rory O’Neill January 06 2022
Haar today, gone tomorrow: EPO's brief BoA move raises queries Lawyers welcomed plans to move the Boards of Appeal back to the centre of Munich, but expressed concerns over the level of accountability at the EPO By Rory O’Neill January 05 2022
This week in IP: EPO rejects DABUS appeal, M&S sues Aldi again, and more J&J must face whistleblower patent case; Malaysia introduces 20-year jail term for piracy; InterDigital loses injunction bid against Lenovo in UK By Patrick Wingrove & Rory O'Neill & Sukanya Sarkar December 24 2021
Opinion: ‘These aren’t murder trials!’ Get on with VICO An EPO consultation on virtual hearings has concluded that the majority of users are happy with the format – and of course they are, it’s common sense. By Max Walters December 15 2021
Drug-access backers may push know-how sharing in WHO deal Advocates say the new pandemic preparedness treaty will be a good opportunity to promote a refocus of the debate away from forced licensing By Rory O’Neill December 09 2021
VICO marks ‘levelling up’ for D&I at EPO, lawyers say VICO has made oral proceedings more accessible for lawyers with disabilities and young families, several practitioners argue By Rory O’Neill December 02 2021
This week in IP: Nokia hits 4,000 5G SEP families, Moderna and NIH debate patent creds,... AC Milan loses stationery application bid; China dominates world patent filings; Sanya city offers patent subsidies; newspaper appeals Markle copyright case; US congressman tries to abolish PTAB; Federal Circuit clari... By Max Walters & Rani Mehta & Rory O’Neill & Sukanya Sarkar November 12 2021
EPO must discourage speculative filings, say pharma counsel The G2/21 referral on plausibility risks turning the clock back to a wave of ‘prophetic’ patent filings seen in the 1990s, say in-house sources By Rory O’Neill November 11 2021
